# Three Months of Weekly Rifapentine and Isoniazid for M. Tuberculosis Infection

> **NCT00023452** · PHASE3 · COMPLETED · sponsor: **Centers for Disease Control and Prevention** · enrollment: 8053 (actual)

## Conditions studied

- Tuberculosis

## Interventions

- **DRUG:** RPT + INH once weekly for 3 months given by DOT
- **DRUG:** Isoniazid (INH) daily for 9 months

## Key facts

- **NCT ID:** NCT00023452
- **Lead sponsor:** Centers for Disease Control and Prevention
- **Sponsor class:** FED
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2001-06
- **Primary completion:** 2010-10
- **Final completion:** 2013-09
- **Target enrollment:** 8053 (ACTUAL)
- **Last updated:** 2024-08-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00023452

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00023452, "Three Months of Weekly Rifapentine and Isoniazid for M. Tuberculosis Infection". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00023452. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*